Gulf International Bank UK Ltd lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.4% during the 1st quarter, Holdings Channel reports. The firm owned 29,147 shares of the biopharmaceutical company’s stock after selling 703 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,471,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Nisa Investment Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 10.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock worth $915,000 after purchasing an additional 700 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Alnylam Pharmaceuticals by 60.2% in the fourth quarter. Bank of Montreal Can now owns 15,862 shares of the biopharmaceutical company’s stock worth $2,015,000 after buying an additional 5,959 shares during the period. Gateway Investment Advisers LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $454,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 7.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 262,416 shares of the biopharmaceutical company’s stock worth $33,340,000 after buying an additional 17,866 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $165,000. 90.56% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals opened at $98.96 on Wednesday, according to MarketBeat Ratings. The company has a quick ratio of 14.61, a current ratio of 14.61 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $10.13 billion, a price-to-earnings ratio of -18.26 and a beta of 2.73. Alnylam Pharmaceuticals, Inc. has a 12-month low of $62.96 and a 12-month high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.47) by $0.06. The firm had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative net margin of 565.20% and a negative return on equity of 36.81%. The company’s revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.25) earnings per share. analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 EPS for the current fiscal year.
Several research analysts have commented on the stock. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 10th. Stifel Nicolaus decreased their target price on shares of Alnylam Pharmaceuticals from $107.00 to $95.00 and set a “hold” rating for the company in a report on Friday, May 4th. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals to $118.00 and set an “equal weight” rating for the company in a report on Monday, May 7th. Finally, BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, March 14th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $137.05.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 7,221 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, March 26th. The shares were sold at an average price of $136.54, for a total value of $985,955.34. Following the completion of the sale, the chief operating officer now directly owns 7,221 shares in the company, valued at $985,955.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Laurie Keating sold 1,562 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $149.83, for a total transaction of $234,034.46. Following the completion of the sale, the senior vice president now owns 16,062 shares of the company’s stock, valued at $2,406,569.46. The disclosure for this sale can be found here. Insiders sold 198,620 shares of company stock valued at $28,404,143 over the last quarter. Corporate insiders own 3.70% of the company’s stock.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.